A clinical trial to study the effects and safety of 3 drugs in varied combinations, namely 1% Luliconazole cream plus 1% Ciclopirox Olamine cream, 1% Luliconazole cream plus 0.25% Amorolfine cream and 1% Luliconazole cream alone in the treatment of ringworm, a fungal infection of skin.
- Conditions
- Health Condition 1: B354- Tinea corporis
- Registration Number
- CTRI/2022/12/048431
- Lead Sponsor
- SRM Medical College Hospital & Research Centre, SRMIST, Potheri
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Patients of age 18years to 60 years, attending dermatology OPD of our hospital, and diagnosed to have Tinea corporis/cruris
2. Positive KOH mount test from skin scraping
3. Patients With mild to moderate extent of disease (less than 10% BSA involvement) and who are suitable for topical-only antifungal therapy.
1.Patients with known allergy to azole antifungals, Amorolfine or Ciclopiroxolamine.
2.Pregnancy/ lactation
3.Patients with dermatophytosis affecting nails / scalp/ palms / soles
4.Patients with clinical features suggestive of secondary bacterial infections
5.Patients on immunosuppressive therapy
6.Patients who had used any topical medications for the tinea corporis/cruris lesions, in the last 2 weeks, or any systemic antifungal medications in the last 1 month.
7.Patients who are not willing to participate in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.To compare the scores of clinical parameters (Pruritus, erythema and scaling) and mycological status (KOH mount assessment) of combination of topical 1% Luliconazole cream and 1% ciclopiroxolamine cream, combination of topical 1% Luliconazole cream and 0.25% Amorolfine cream and 1% Luliconazole cream alone, in the treatment of Tinea corporis and Tinea crurisTimepoint: At end of 2nd week, 4th week and 6th week
- Secondary Outcome Measures
Name Time Method 1.To compare the safety (based on evaluation for any adverse effects)of combination of topical 1% Luliconazole cream and 1% ciclopiroxolamine cream, combination of topical 1% Luliconazole cream and 0.25% Amorolfine cream and 1% Luliconazole cream alone, in the treatment of Tinea corporis and Tinea crurisTimepoint: At end of 2nd week, 4th week and 6th week